spironolactone has been researched along with oridonin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, H; Jiang, J; Li, D; Wang, L; Xu, J; Xu, S; Yao, H; Zhang, Y | 1 |
| Cai, H; Jiang, B; Li, D; Liu, G; Sun, Y; Wang, L; Wang, Y; Wu, X; Xu, J; Yao, H | 1 |
| He, C; Jia, Y; Ni, X; Wu, X; Xu, J; Xu, S; Yao, H; Zhou, K | 1 |
3 other study(ies) available for spironolactone and oridonin
| Article | Year |
|---|---|
The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Diterpenes; Diterpenes, Kaurane; Female; Humans; K562 Cells; Mice; Spironolactone; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2012 |
Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Diterpenes; Diterpenes, Kaurane; Flow Cytometry; Humans; Inhibitory Concentration 50; Liver Neoplasms; Models, Molecular; Paclitaxel; Spironolactone | 2013 |
Spirolactone-type and enmein-type derivatives as potential anti-cancer agents derived from oridonin.
Topics: Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Diterpenes; Diterpenes, Kaurane; Esters; Humans; Reactive Oxygen Species; Spironolactone; Structure-Activity Relationship | 2022 |